On July 11, 2025, Raymond James initiated coverage on Janux Therapeutics (JANX, Financial), providing it with an "Outperform" rating. This new coverage highlights the interest and potential seen in Janux Therapeutics by one of the well-known analysts in the industry, Sean McCutcheon.
The analyst set the price target for Janux Therapeutics (JANX, Financial) at $65.00 USD. This price target reflects the optimism in the company's future performance and market potential.
The announcement by Raymond James offers insights into the strategic direction and expected advancement of Janux Therapeutics (JANX, Financial) in the competitive biotech sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Janux Therapeutics Inc (JANX, Financial) is $83.55 with a high estimate of $200.00 and a low estimate of $25.00. The average target implies an upside of 226.22% from the current price of $25.61. More detailed estimate data can be found on the Janux Therapeutics Inc (JANX) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, Janux Therapeutics Inc's (JANX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Janux Therapeutics Inc (JANX, Financial) in one year is $5.90, suggesting a downside of 76.96% from the current price of $25.61. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Janux Therapeutics Inc (JANX) Summary page.
